Oncology Xagena
The outcomes and therapy of advanced urothelial carcinoma ( UC ) patients following discontinuation of PD-1/PD-L1 inhibitors are unclear. Researchers performed a retrospective analysis to examine ...
The PARP inhibitor, Olaparib ( Lynparza ) has shown clinical activity in subsets of recurrent ovarian cancer patients. Researchers have hypothesized increased DNA damage by Olaparib may complement a ...
Myeloid-derived suppressor cells ( MDSC ) are expanded in cancer and promote immune suppression. A research has shown that Ibrutinib ( Imbruvica ) inhibits migration and immunosuppressive function o ...
